for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indivior PLC

INDV.L

Latest Trade

115.60GBp

Change

0.10(+0.09%)

Volume

733,747

Today's Range

112.50

 - 

116.40

52 Week Range

32.90

 - 

165.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
115.50
Open
115.00
Volume
733,747
3M AVG Volume
52.12
Today's High
116.40
Today's Low
112.50
52 Week High
165.80
52 Week Low
32.90
Shares Out (MIL)
733.48
Market Cap (MIL)
894.85
Forward P/E
-42.26
Dividend (Yield %)
--

Next Event

Full Year 2020 Indivior PLC Earnings Release

Latest Developments

More

Indivior Plc Says Co Streamlining Some Corporate Functions, Reducing Discretionary Spending

Indivior Says Howard Pien Notified Board Of His Resignation With Immediate Effect

Indivior HY Reported Operating Loss $165 Mln Vs Operating Profit $163 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

103-105 Bath Road

SL1 3UH

United Kingdom

+44.1753.217800

http://indivior.com/

Executive Leadership

Daniel Tasse

Interim Chairman of the Board

Mark Crossley

Chief Executive Officer, Executive Director

Ryan Preblick

Interim Chief Financial Officer

Jon Fogle

Chief Human Resource Officer

Christian Heidbreder

Chief Scientific Officer

Key Stats

1.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.1K

2018

1.0K

2019

0.8K

2020(E)

0.6K
EPS (USD)

2017

0.360

2018

0.370

2019

0.230

2020(E)

-0.033
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.80
Price To Book (MRQ)
19.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
489.66
LT Debt To Equity (MRQ)
472.41
Return on Investment (TTM)
-16.98
Return on Equity (TTM)
-9.75

Latest News

Latest News

Indivior to pay $600 million to settle U.S. opioid treatment marketing claims

Indivior Plc <INDV.L> has agreed to pay $600 million and have a subsidiary plead guilty to a felony charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

BRIEF-Indivior Notes Ex-CEO Shaun Thaxter In Agreement With U.S. Dept Of Justice

* INDIVIOR PLC - NOTES THAT SHAUN THAXTER, ITS FORMER CHIEF EXECUTIVE OFFICER, ENTERED INTO AN AGREEMENT WITH U.S. DEPARTMENT OF JUSTICE

Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Shaun Thaxter, the former chief executive of drugmaker Indivior Plc <INDV.L>, pleaded guilty on Tuesday to a criminal charge arising out of a U.S. Justice Department investigation into the marketing of its opioid addiction treatment Suboxone.

Ex-CEO of opioid treatment maker Indivior pleads guilty in U.S.

Shaun Thaxter, the former chief executive of drugmaker Indivior Plc, pleaded guilty on Tuesday to a criminal charge arising out of a U.S. Justice Department investigation into the marketing of its opioid addiction treatment Suboxone.

BRIEF-Indivior Says 24-Month Outcomes Of Recover Study Presented

* INDIVIOR PLC - 24-MONTH OUTCOMES OF RECOVER STUDY PRESENTED Source text for Eikon: Further company coverage:

BRIEF-Indivior Says Chair Howard Pien To Take Leave Of Absence For Medical Reasons

* INDIVIOR PLC ANNOUNCES THAT CHAIR, HOWARD PIEN, IS TO TAKE A LEAVE OF ABSENCE FOR MEDICAL REASONS

BRIEF-Indivior Gets Nod For Subutex For Substitution Treatment Of Opioid Dependence In Sweden

* INDIVIOR RECEIVES APPROVAL FOR SUBUTEX® PROLONGED RELEASE SOLUTION FOR INJECTION, 100MG AND 300MG FOR SUBSTITUTION TREATMENT OF OPIOID DEPENDENCE IN SWEDEN Source text for Eikon: Further company coverage:

BRIEF-Indivior PLC Shifts AGM Venue

* INDIVIOR PLC - AGM WILL NO LONGER BE HELD AT ORIGINAL VENUE AND MEETING WILL NOW BE HELD AT COMPANY'S REGISTERED OFFICE

BRIEF-Indivior Says Safety Profile Of Up To 12-Month Sublocade Treatment Consistent With Transmucosal Buprenorphine

* INDIVIOR - SAFETY PROFILE OF UP TO 12-MONTH SUBLOCADE TREATMENT CONSISTENT WITH TRANSMUCOSAL BUPRENORPHINE, WITH ANTICIPATED INJECTION-SITE REACTIONS EXCEPTION

Indivior withdraws 2020 forecast on coronavirus-led uncertainty

British drugmaker Indivior PLC <INDV.L> withdrew its annual financial forecast on Wednesday, citing uncertainties due to the coronavirus pandemic.

Indivior withdraws 2020 forecast on coronavirus-led uncertainty

British drugmaker Indivior PLC withdrew its annual financial forecast on Wednesday, citing uncertainties due to the coronavirus pandemic.

BRIEF-Indivior Says It Does Not Currently Expect To Have Any Material Supply Interruptions

* INDIVIOR PLC - STATEMENT ON THE CORONAVIRUS AND GLOBAL SUPPLY OF MEDICINES

BRIEF-Indivior Says Daniel Tassé To Step Down As Chair Of Audit Committee

* GRAHAM HETHERINGTON WILL TAKE ON ROLE OF CHAIR OF AUDIT COMMITTEE Source text for Eikon: Further company coverage:

BRIEF-Indivior Q4 Adjusted Net Loss $37 Mln Versus Profit Of $67 Mln Reported Last Year

* INDIVIOR PLC QTRLY NET REVENUE $133 MILLION VERSUS $236 MILLION

Indivior revenue falls as opioid addiction drug's market share plummets

Indivior Plc <INDV.L> reported a 19% slump in third-quarter revenue on Thursday as the British drugmaker's best-selling opioid addiction treatment lost more than half of its market share to cheaper generic rivals in the United States.

Indivior third-quarter revenue falls as opioid drug loses market share

Indivior Plc reported a 19% fall in quarterly revenue on Thursday, as the embattled British drugmaker lost market share of its best-selling opioid addiction treatment Suboxone to cheaper rivals in the United States.

Embattled drugmaker Indivior raises forecasts on Suboxone strength

Indivior Plc on Tuesday raised its full-year forecasts as the embattled British drugmaker's best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.

Indivior raises full-year revenue forecast on Suboxone strength

Indivior PLC on Tuesday raised its full-year revenue forecast, banking on the strength of its opioid-addiction treatment Suboxone.

Indivior profit rises on slower-than-expected Suboxone market share loss

Drugmaker Indivior Plc <INDV.L> reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up